Masami Yamada

This inventor holds 25 USPTO granted patents and 6 published patent applications and 8 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masami Yamada. Retrieved from https://idiyas.com/inventor/masami-yamada-igukr5ea

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 6)

% Patents Active = 96.0

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

San Diego, CA (US) (2014)
Kanagawa, JP (2016 - 2022)

Company Filing History:

25 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compound

Pyrido[1,2-a]Pyrimidines

Pyrazino[1,2-a]Pyrimidines

Cholinergic Muscarinic M1 Receptor

Positive Allosteric Modulator

Isoindoline Derivatives

Alzheimer's Disease

Nitrogen-Containing Compounds

Aromatic Ring Compound

Bicyclic Heterocyclic Compound

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378256 - Heterocyclic compound (2025-08-05),

2. 11407748 - Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function (2022-08-09),

3. 11236099 - Heterocyclic compound (2022-02-01),

4. 10899752 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2021-01-26),

5. 10865200 - Nitrogen-containing heterocyclic compound (2020-12-15),

6. 10548899 - Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity (2020-02-04),

7. 10548877 - Aromatic ring compound (2020-02-04),

8. 10457670 - Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease (2019-10-29),

9. 10428056 - Heterocyclic compound (2019-10-01),

10. 10323027 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2019-06-18),

11. 10208046 - Nitrogen-containing heterocyclic compound (2019-02-19),

12. 10087150 - Heterocyclic compound (2018-10-02),

13. 9878989 - Heterocyclic compound (2018-01-30),

14. 9868725 - Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease (2018-01-16),

15. 9789084 - Nitrogen-containing heterocyclic compound (2017-10-17),

Title: The Innovative Contributions of Masami Yamada

Introduction

Masami Yamada, based in Kanagawa, Japan, is a prominent inventor known for her significant contributions to the field of pharmaceuticals. With a total of 24 patents to her name, she has dedicated her career to developing innovative solutions that address various medical conditions.

Latest Patents

Among Masami Yamada's latest contributions are two noteworthy patents. The first patent focuses on substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines that enhance AMPA receptor function. This invention aims to provide a heterocyclic compound with an AMPA receptor potentiator effect, offering potential therapeutic benefits for conditions such as depression, Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The compound is represented by a specific formula detailed in the patent specification.

The second patent presents a heterocyclic compound that may be beneficial for the prophylaxis or treatment of constipation and related conditions. Similar to her previous work, this invention also includes a compound described by a specified formula.

Career Highlights

Masami Yamada has made her mark in the pharmaceutical industry while working at Takeda Pharmaceutical Company Limited. Her role in the organization has allowed her to develop cutting-edge pharmaceutical compounds that contribute to advancements in medical treatments. Her creativity, coupled with a passion for innovation, has led to substantial advancements in her field.

Collaborations

Yamada’s success is not solely attributed to her efforts; she has also collaborated with notable colleagues, including Shinkichi Suzuki and Takahiro Sugimoto. These partnerships have fostered a collaborative environment that has further driven innovation within their projects.

Conclusion

Masami Yamada's work exemplifies the spirit of innovation in the pharmaceutical industry. Through her extensive patent portfolio and collaborative efforts, she has played a crucial role in developing compounds that promise to improve healthcare outcomes. Her dedication to addressing pressing medical challenges sets her apart as a leading inventor in her field.

Profile summary based on public USPTO records.